G+FLAS Life Sciences

About:

G+FLAS Life Sciences is a biotech company that develops genome-edited crops including vitamin D3 tomatoes.

Website: http://gflas.com

Top Investors: New Flight, TIPS Program, Korea Development Bank, Smilegate Investment, Timepolio Asset Management

Description:

GFLAS Life Sciences, Inc. is poised to disrupt the agricultural biotechnology sector with its pioneering advancements in CRISPR-Cas genome editing technology. Founded by Dr. Sunghwa Choe in 2014, GFLAS has swiftly established itself as a leader in biotech innovation, dedicated to enhancing human health and promoting agricultural sustainability through cutting-edge genetic engineering solutions. Our flagship innovation, the world's first vitamin D3-enriched tomatoes, addresses a critical market need by transforming the traditional tomato industry. Tomatoes are one of the most consumed vegetables globally, with the US fresh tomato market alone valued at approximately $18 billion annually, assuming an average price of $1.5 per kilogram. The consumer market value is even more substantial, estimated between $27 to $31.5 billion annually. By introducing vitamin D3-enriched tomatoes, GFLAS not only adds significant nutritional value to a staple food product but also creates a unique selling proposition that meets the increasing consumer demand for functional foods. The strategic partnership with Bayer, a global leader in agricultural science, underscores the commercial viability and substantial market potential of our technology. This collaboration has facilitated the transfer of GFLAS's vitamin D3 tomato technology to Bayer Crio Science in the USA, providing a robust pathway for large-scale commercialization and global market penetration. This partnership not only validates our technological prowess but also positions us for significant growth in the global agricultural market. Our vitamin D3-enriched tomatoes offer numerous advantages over traditional vitamin D supplements. They provide a sustainable, plant-based source of vitamin D3, catering to vegans, vegetarians, and individuals with dietary restrictions or limited sun exposure. Unlike vitamin D3 derived from animal sources, our tomatoes are free from the risk of chemical contamination, making them a safer and more natural alternative. Furthermore, incorporating vitamin D3 into a widely consumed food product enhances consumer acceptance and adherence to recommended dietary intakes. The market potential for our innovations is immense. By capturing a significant share of the $18 billion US wholesale tomato market, our vitamin D3-enriched tomatoes can appeal to health-conscious consumers and address the needs of populations at risk of vitamin D deficiency. Additionally, our enhanced CRISPR-Cas technologies offer transformative possibilities across various agricultural applications, positioning GFLAS for sustained growth and profitability. We are now seeking investment to accelerate our expansion and capitalize on the lucrative opportunities within the US market and beyond. Our financial projections indicate substantial growth, with a target of achieving 30% market share within four years. The infusion of capital will support scaling up production, enhancing quality control, and expanding distribution and marketing efforts. GFLAS Life Sciences invites private equity funds and strategic investors to join us in this groundbreaking venture. With our cutting-edge technologies, strong partnerships, and clear market potential, GFLAS is uniquely positioned to deliver substantial returns on investment while making a profound positive impact on global health and sustainability. We look forward to discussing this exciting investment opportunity further and exploring how we can work together to bring our revolutionary products to market.